GT Biopharma Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for GT Biopharma.

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for GT Biopharma.

Recommendation Trends

Rating	Jul '24	Aug '24	Sep '24	Oct '24	Nov '24
Strong Buy	1	1	1	1	1
Buy	0	0	0	0	0
Hold	1	1	1	1	1
Sell	0	0	0	0	0
Strong Sell	0	0	0	0	0
Total	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jonathan Aschoff Roth MKM	Roth MKM	Strong Buy Initiates $11	Strong Buy	Initiates	$11	+2,329.87%	Dec 2, 2024
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $150	Strong Buy	Reiterates	$150	+33,034.53%	Aug 8, 2023
Tony Butler EF Hutton	EF Hutton	Hold Reiterates $60	Hold	Reiterates	$60	+13,153.81%	Aug 7, 2023
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $150	Strong Buy	Reiterates	$150	+33,034.53%	Jun 5, 2023
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $150	Strong Buy	Reiterates	$150	+33,034.53%	May 17, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.71

from -6.68

EPS Next Year

-0.53

from -0.71

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-61.81	-19.66	-5.64	-6.94	-6.68	-0.71	-0.53
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-0.74	-0.55
Avg	-0.71	-0.53
Low	-0.69	-0.51

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.